Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junqi Niu

Showing results (201-210 of 280) with videos related to

Pageof 28
Sort By:
Zhonghua Nei Ke Za Zhi|December 18, 2015
[The efficacy and prognostic predictors of different treatment courses with pegylated interferon α-2a and ribavirin combination in recurrent chronic hepatitis C patients]Huiying Rao, Ruifeng Yang, Jia Shang, et al.
Emerging Microbes & Infections|July 4, 2020
Profiles of COVID-19 clinical trials in the Chinese Clinical Trial RegistryPeng Xu, Xiangyu Xing, Keying Yu, et al.
Cell Research|August 27, 2014
Persistent hepatitis C virus infections and hepatopathological manifestations in immune-competent humanized miceJizheng Chen, Yang Zhao, Chao Zhang, et al.
Antiviral Therapy|January 24, 2023
Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participantsLiviawati S Wu, Yue Hu, Edward J Gane, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 5, 2011
Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis BEdward J Gane, Yuming Wang, Yun-Fan Liaw, et al.
Journal of Virology|September 29, 2023
EGR1 functions as a new host restriction factor for SARS-CoV-2 to inhibit virus replication through the E3 ubiquitin ligase MARCH8Yinghua Zhao, Liyan Sui, Ping Wu, et al.
Journal of Virology|October 3, 2023
Activation of AIM2 by hepatitis B virus results in antiviral immunity that suppresses hepatitis C virus during coinfectionYongqi Li, Yang Yang, Tianyang Li, et al.
Advances in Therapy|September 3, 2015
Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis BJin-Lin Hou, Daozheng Xu, Guangfeng Shi, et al.
Scientific Reports|July 21, 2017
Quinolinate Phosphoribosyltransferase is an Antiviral Host Factor Against Hepatitis C Virus InfectionZhilong Wang, Yanhang Gao, Chao Zhang, et al.
Journal of Hepatology|July 8, 2019
ALDH2 deficiency promotes alcohol-associated liver cancer by activating oncogenic pathways via oxidized DNA-enriched extracellular vesiclesWonhyo Seo, Yanhang Gao, Yong He, et al.
Pageof 28

Showing results (201-210 of 280) with videos related to

Sort By:
Pageof 28
Zhonghua Nei Ke Za Zhi|December 18, 2015
[The efficacy and prognostic predictors of different treatment courses with pegylated interferon α-2a and ribavirin combination in recurrent chronic hepatitis C patients]Huiying Rao, Ruifeng Yang, Jia Shang, et al.
Emerging Microbes & Infections|July 4, 2020
Profiles of COVID-19 clinical trials in the Chinese Clinical Trial RegistryPeng Xu, Xiangyu Xing, Keying Yu, et al.
Cell Research|August 27, 2014
Persistent hepatitis C virus infections and hepatopathological manifestations in immune-competent humanized miceJizheng Chen, Yang Zhao, Chao Zhang, et al.
Antiviral Therapy|January 24, 2023
Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participantsLiviawati S Wu, Yue Hu, Edward J Gane, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|April 5, 2011
Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis BEdward J Gane, Yuming Wang, Yun-Fan Liaw, et al.
Journal of Virology|September 29, 2023
EGR1 functions as a new host restriction factor for SARS-CoV-2 to inhibit virus replication through the E3 ubiquitin ligase MARCH8Yinghua Zhao, Liyan Sui, Ping Wu, et al.
Journal of Virology|October 3, 2023
Activation of AIM2 by hepatitis B virus results in antiviral immunity that suppresses hepatitis C virus during coinfectionYongqi Li, Yang Yang, Tianyang Li, et al.
Advances in Therapy|September 3, 2015
Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis BJin-Lin Hou, Daozheng Xu, Guangfeng Shi, et al.
Scientific Reports|July 21, 2017
Quinolinate Phosphoribosyltransferase is an Antiviral Host Factor Against Hepatitis C Virus InfectionZhilong Wang, Yanhang Gao, Chao Zhang, et al.
Journal of Hepatology|July 8, 2019
ALDH2 deficiency promotes alcohol-associated liver cancer by activating oncogenic pathways via oxidized DNA-enriched extracellular vesiclesWonhyo Seo, Yanhang Gao, Yong He, et al.
Pageof 28